Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Completed · Phase 3
Conditions studied: Prostate Cancer
In brief
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue and may improve quality of life and help patients live more comfortably. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin and bicalutamide may fight cancer by stopping the production of androgens. It is not yet known whether radiation therapy is more effective with or without goserelin and bicalutamide in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of high-dose radiation therapy with or without bicalutamide and goserelin in treating patients who have prostate cancer.
Key facts
- Study ID
- NCT00067015
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 3
- Starts
- 2003-05-01
- Expected to finish
- 2008-09-01
- Last updated by the study team
- 2015-12-22
Who can join
Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.